Agony & Ecstasy Of Sarepta: A New FDA Rare Disease Standard?

Even though investors viewed the FDA's willingness to give Sarepta another chance to provide more data as a positive step, most analysts said it was simply delaying the inevitable of rejecting the firm's Duchenne muscular dystrophy drug eteplirsen. Others have cautioned the FDA may be setting a new standard for approving rare disease drugs, in which other companies may demand similar attention.

The FDA has done it again – put off its decision on Sarepta Therapeutics Inc.'s new drug application (NDA) for its Duchenne muscular dystrophy (DMD) drug eteplirsen, this time telling the firm regulators want dystrophin data, as measured by Western blot, from biopsies already obtained from the company's ongoing PROMOVI confirmatory study.

Sarepta said it would submit data to the FDA "in the coming weeks" from biopsy samples from 13 patients who...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip